参考文献/References:
[1] GEE W F, HOLTGREWE H L, ALBERTSEN P C, et al. Practice trends in the diagnosis and management of prostate cancer in the United States[J]. The Journal of Urology, 1995, 154(1): 207-208.
[2] TERADA N, AKAMATSU S, KOBAYASHI T, et al. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications[J]. Therapeutic Advances in Medical Oncology, 2017, 9(8): 565-573.
[3] 周利群，那彦群，黄有媛，等．良性前列腺增生与前列腺癌患者血清总 PSA水平与游离 PSA比值的比较 [J].中华泌尿外科杂志 , 2002, 23(6): 354-357． ZHOU Liqun, NA Yanqun,HUANG Youyuan,et al. Serum total PSA and the ratio of free to total PSA in patients of benign prostatic hyperplasia and prostate cancer[J]. Chinese Journal of Urology, 2002, 23(6):354-357.
[4] AL SAIDI S S, AL RIYAMI N B, AL MARHOON M S, et al. Validity of prostate health index and percentage of [-2] pro-prostate-specific antigen as novel biomarkers in the diagnosis of prostate cancer: omani tertiary hospitals experience[J]. Oman Medical Journal, 2017, 32(4): 275-283.
[5] PERDONà S, BRUZZESE D, FERRO M, et al. Prostate health index (PHI) and prostate cancer antigen 3 (PCA3) signi.cantly improve diagnostic accuracy in patients undergoing prostate biopsy[J]. The Prostate, 2013, 73(3): 227-235.
[6] LAZZERI M, HAESE A, ALBERTO A, et al. Clinical performance of serum prostate-speci.c antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the Prometheus[J]. BJU International, 2013, 112(3): 313-321.
[7] FRANCO J, AFONASO F, BERNARDES C, et al. KLK3 gene rs266882 polymorphism in prostatic tissue[J]. Annals of Medicine, 2019, 51(sup1): 47.
[8] CATALONA W J. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer[J]. New England Journal of Medicine, 1991, 324(17): 1156-1161.
[9] FILELLA X, FOJ L, AUGé J M, et al. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer[J]. Clinical Chemistry and Laboratory Medicine, 2014, 52(9): 1347-1355.
[10] 覃斌，梁阳冰，梁毅文，等．直肠超声引导下经会阴和直肠前列腺穿刺活检术诊断灰区前列腺癌的对比研究 [J].中华男科学杂志 , 2016, 22(5):477-479. QIN Bin, LIANG Yangbing, LIANG Yiwen, et al.Comparative study of transperineal and rectal ultrasound-guided prostate biopsy in the diagnosis of gray area prostate cancer[J]．National Journal of Andrology, 2016, 22(5):477-479.
[11] 吴义启，刘修恒．前列腺健康指数对前列腺癌的诊断价值 [J].中华实验外科杂志 , 2015, 32(5):1190-1192. prostate health index for prostate cancer [J]. Chinese Journal of Experimental Surgery,2015, 32(5):1190-1192.
[12] YOO M, YEO W S. Determining the ratio of two types of prostate specific antigens with biochips and Gold nanoparticles for accurate prostate cancer diagnosis[J]. Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry, 2016, 32(10): 1117-1121.
[13] 申景涛 , 郭万华 , 辛小燕 , 等 .PSAD, tPSA , fPSA/ tPSA在前列腺癌“诊断灰色带”中的 ROC曲线分析 [J].现代检验医学杂志 , 2007, 22(5):59-61. SHEN Jingtao, GUO Wanhua, XIN Xiaoyan, et al. ROC curve analysis of fPSA/tPSA and PASD for prostate cancer with tPSA in diagnostic gray zone[J]. Journal of Modern Laboratory Medicine, 2007, 22(5):59-61.
[14] 梁震，朱军，康家旗，等．双参数磁共振 PI-RADS联合 PSA相关指标在首次前列腺穿刺活检中的诊断价值 [J].中华泌尿外科杂志 , 2019, 40(10):768-773. LIANG Zhen, ZHU Jun, KANG Jiaqi, et al. Diagnostic value of biparameter magnetic resonance imaging of PI-RADS and PSA related markers in first prostate biopsy[J]. Chinese Journal of Urology, 2019, 40(10):768-773.
[15] 孙珂，高佃军． tPSA灰区 fPSA/tPSA与 PSAD对前列腺癌与前列腺增生伴前列腺炎的诊断价值 [J]．临床医学 , 2019, 39(4): 21-23. SUN Ke, GAO Dianjun. Diagnostic effectiveness of fPSA/tPSA and PSAD in PSA gray zone for diagnosis of prostate cancer and prostatic hyperplasia accompanied with prostatitis[J]. Clinical Medicine, 2019, 39(4):21-23.
[16] 闫瑾，李小珍，杨飞．外周血前列腺癌抗原 3基因检测对前列腺癌诊断的 meta分析 [J]．现代检验医学杂志 , 2019, 34(5):40-44,51. YAN Jin, LI Xiaozhen, Yang Fei. Validity of PCA3 gene test in peripheral blood for prostate cancer diagnosis:a meta-analysis [J]. Journal of Modern Laboratory Medicine, 2019, 34(5):40-44,51.
[17] SOKOLL L J, SANDA M G, FENG Ziding, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2] proPSA: improving prostate cancer detection and correlating with cancer aggressiveness[J]. Cancer Epidemiology, Biomarkers & Prevention, 2010, 19(5): 1193-1200.
[18] CHIU P K F, ROOBOL M J, TEOH J Y, et al. Prostate health index (PHI) and prostate-speci.c antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume[J]. International Urology and Nephrology, 2016, 48(10): 1631-1637.
[19] NA Rong, YE Dingwei, LIU Fang, et al. Performance of serum prostate-speci.c antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population[J]. The Prostate, 2014, 74(15):1569-1575.
[20] 黄宜，王文涓，许静，等． p2PSA及其相关指标 PHI在前列腺癌诊断中的应用价值 [J]．检验医学， 2019, 34(7): 600-604. HUANG Yi, WANG Wenjuan, XU Jing, et al. Role of p2PSA and its related marker PHI in the diagnosis of prostate cancer[J]. Laboratory Medicine, 2019, 34(7):600-604.
[21] 黑炜翔 , 杨宗盛 , 夏成兴 , 等 .FPSA/TPSA,PSAD联合多参数磁共振成像 PI-RADS评分在诊断 PSA灰区前列腺癌中的作用 [J]．国际泌尿系统杂志 , 2020, 40(2):234-239. HEI Weixiang, YANG Zongsheng, XIA Chengxing, et al. The role of FPSA/TPSA, PSAD combined with multi-parameter magnetic resonance imaging 418-423. PI-RADS score in the diagnosis of PSA gray area prostate cancer[J]. International Journal of Urology and Nephrology, 2020, 40(2):234-239.
[22] 方建雄 , 刘久敏 , 蒲小勇 , 等 .尿液中 CXCL16联合 PSAD，fPSA%对 PSA灰区前列腺癌患者的诊断价值 [J]．中华腔镜泌尿外科杂志 (电子版 )，2020, 14(3):171-175. FANG Jianxiong, LIU Jiumin, PU Xiaoyong, et al. Combined detection of CXCL16, PSAD and fPSA% for the clinical diagnosis of prostate cancer with PSA in diagnostic gray zone[J]. Chinese Journal of Endourology (Electronic Edition), 2020, 14(3):171-175.
相似文献/References:
[1]廖洪利,米叶赛尔·阿不都拉.粘着斑激酶在前列腺癌中表达的研究[J].现代检验医学杂志,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
LIAO Hong-li,MIYESAIER·Abdula.Research on Expression of FAK in Prostate Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(01):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
[2]范维肖,刁艳君,马越云,等.超速离心法与QIAGEN膜亲和柱法提取前列腺癌细胞培养上清外泌体的方法学比较[J].现代检验医学杂志,2019,34(03):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
FAN Wei-xiao,DIAO Yan-jun,MA Yue-yun,et al.Comparison of Ultracentrifugation and Membrane Based-Affinity ColumnMethods in Exosome Isolation from Supernatants of Prostate Cancer Cells[J].Journal of Modern Laboratory Medicine,2019,34(01):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
[3]何 跃,梁 晶,文礼红,等.前列腺癌患者血清IL-17和IL-35水平表达与临床病理特征以及预后的关系研究[J].现代检验医学杂志,2021,36(04):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
HE Yue,LIANG Jing,WEN Li-hong,et al.Study on the Relationship between Serum IL-17, IL-35 Levels andClinicopathological Features and Prognosis in Patients with Prostate Cancer[J].Journal of Modern Laboratory Medicine,2021,36(01):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
[4]荣 蓉a,古 颖a,高 翔a,等.前列腺癌组织肝激酶B1，Rab鸟嘌呤核苷酸交换因子-5mRNA表达水平与临床病理特征和预后的相关性研究[J].现代检验医学杂志,2021,36(06):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
RONG Rong,GU Ying,GAO Xiang,et al.Correlation between the Expression Levels of Liver Kinase B1, Rab Guanine Nucleotide Exchange Factor-5 mRNA in Prostate Cancer Tissues and Its Clinicopathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(01):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
[5]张士保,朱斐煜,谢瑞玉,等.CircRNA-100395 基因通过启动子区甲基化调控miRNA-136-5p/Smad3 轴促进前列腺癌细胞增殖及侵袭的机制研究[J].现代检验医学杂志,2022,37(05):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
ZHANG Shi-bao,ZHU Fei-yu,XIE Rui-yu,et al.Mechanism of CircRNA-100395 Promoter Methylation Promoting Prostate Cancer Cells Proliferation and Invasion by Regulating miRNA-136-5p/Smad3 Axis[J].Journal of Modern Laboratory Medicine,2022,37(01):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
[6]阴铭迪,李 林.前列腺癌实验室诊断的最新进展[J].现代检验医学杂志,2022,37(05):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
YIN Ming-di,LI Lin.Recent Advances in Laboratory Diagnosis of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2022,37(01):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
[7]郑江婷,寸淑娥,尹 冶,等.长链非编码RNA 在前列腺癌治疗抵抗中作用机制的研究进展[J].现代检验医学杂志,2023,38(01):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
ZHENG Jiang-ting,CUN Shu-e,YIN Ye,et al.Research Progress of Long Non-coding RNA in the Therapeutic Resistance of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2023,38(01):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
[8]孙 飞,黎春明.基于免疫细胞组织浸润的免疫评分模型预测前列腺癌免疫治疗效果及预后分析研究[J].现代检验医学杂志,2023,38(03):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
SUN Fei,LI Chun-ming.Prediction of Immunotherapy Effect and Prognosis of Prostate Cancer Based on Immune Cell Tissue Infiltration Immune Score Model[J].Journal of Modern Laboratory Medicine,2023,38(01):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
[9]姚俊波,贾 波,刘加元,等.前列腺癌患者血清TWEAK 和SREBP-1 水平表达与临床病理特征及无进展生存预后的关系研究[J].现代检验医学杂志,2024,39(03):136.[doi:10.3969/j.issn.1671-7414.2024.05.023]
YAO Junbo,JIA Bo,LIU Jiayuan,et al.Study on the Serum TWEAK and SREBP-1 Levels in Patients with Prostate Cancer and Their Relationship with Clinical Pathological Characteristics and Progression Free Survival Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(01):136.[doi:10.3969/j.issn.1671-7414.2024.05.023]
[10]张 珑,李月峰,吴 涛,等.前列腺癌患者血清miR-138-5p，miR-212-5p 水平表达及与临床预后价值[J].现代检验医学杂志,2024,39(05):30.[doi:10.3969/j.issn.1671-7414.2024.05.006]
ZHANG Long,LI Yuefeng,WU Tao,et al.Expression of Serum miR-138-5p and miR-212-5p Levels and Clinical Prognosis Value in Prostate Cancer[J].Journal of Modern Laboratory Medicine,2024,39(01):30.[doi:10.3969/j.issn.1671-7414.2024.05.006]